An open-label, parallel-group, repeat-dose study to investigate the effects of end stage renal disease and haemodialysis on the pharmacokinetics of ropinirole (study RRL103628).
Latest Information Update: 05 Sep 2023
Price :
$35 *
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Mar 2006 to Apr 2006 as reported by Clinicaltrials.gov.
- 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 09 Feb 2007 New trial record.